SCHEMBL1152547

SCHEMBL1152547

COc1ccc2c(c1)=NC(=O)N=2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.42
CA7 P43166 4/20 0.42
CA9 Q16790 4/20 0.42
CA12 O43570 3/20 0.42
CA2 P00918 3/20 0.42
CA14 Q9ULX7 3/20 0.42
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
GSTP1 P09211 1/20 0.41
CA4 P22748 2/20 0.40
CYP2A6 P11509 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064932 0.78 GFER (0.42) CA1CA7CA9CA12CA2
SCHEMBL29154360 0.75 GRIN2D (0.43) CA1CA7CA9CA12CA2
SCHEMBL6854794 0.72 ALOX5 (0.37) CA1CA7CA9CA12CA2
SCHEMBL11862521 0.71 CA12 (0.43) CA1CA7CA9CA12CA2
SCHEMBL7647130 0.70 CA12 (0.42) CA1CA7CA9CA12CA2
SCHEMBL3226561 0.68 S100A4 (0.39) ALDH1A1HPGDCYP1A2LMNAPOLB
SCHEMBL3228155 0.68 KDM4E (0.35) CA1CA7CA9CA2CA14
SCHEMBL382451 0.68 NPC1 (0.35) ALDH1A1HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL6345650 0.68 PARP1 (0.33) CASP3PDE3BPDE3A
SCHEMBL3795668 0.68 TERT (0.42) ALDH1A1KDM4EHPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107188771-B Chiral synthesis method of gamma-nitrophenol compound 浙江工业大学 2021-08-24 CN claimed
CN-120463725-A Double-cavity tetraimidazolium cyclotomato, and preparation method and application thereof 延安大学 2025-08-12 CN disclosed
CN-107188771-B Chiral synthesis method of gamma-nitrophenol compound 浙江工业大学 2021-08-24 CN disclosed
EP-2290015-B1 NANOSCALE PIGMENT PARTICLE COMPOSITION AND PROCESS FOR PRODUCING THE SAME XEROX CORP (US) 2017-05-24 EP disclosed
EP-2290013-B1 METHODS OF MAKING NANAOSIZED PARTICLES OF BENZOIMIDAZOLONE PIGMENTS XEROX CORP (US) 2017-03-29 EP disclosed
US-9035287-B2 Polymeric materials for use in metal-oxide-semiconductor field-effect transistors POLYERA CORPORATION (US) 2015-05-19 US disclosed
US-20140217395-A1 Polymeric Materials for Use in Metal-Oxide-Semiconductor Field-Effect Transistors POLYERA CORPORATION (US) 2014-08-07 US disclosed
US-20130303516-A1 NOVEL TRIAZINE COMPOUNDS SPHAERA PHARMA PTE. LTD. (SG) 2013-11-14 US disclosed
US-8461351-B2 Sterically bulky stabilizers XEROX CORPORATION (US) 2013-06-11 US disclosed
US-8362270-B2 Self-assembled nanostructures XEROX CORPORATION (US) 2013-01-29 US disclosed
EP-2290013-A2 Methods of making nanosized particles of benzimidazolone pigments Xerox Corporation (US) 2011-03-02 EP disclosed
US-7883574-B2 Methods of making nanosized particles of benzimidazolone pigments XEROX CORPORATION (US) 2011-02-08 US disclosed
US-20100300326-A1 NONPOLAR LIQUID AND SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS XEROX CORPORATION (US) 2010-12-02 US disclosed
WO-2010015037-A1 THERAPEUTIC METHODS AND COMPOSITIONS HOWARD FLOREY INSTITUTE (AU) 2010-02-11 WO disclosed
US-20100035172-A1 NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS XEROX CORPORATION (US) 2010-02-11 US disclosed
US-20100004360-A1 METHODS OF MAKING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS XEROX CORPORATION (US) 2010-01-07 US disclosed
EP-0355024-B1 PROCESS FOR THE PRODUCTION OF CYCLIC UREAS HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-15 EP disclosed
US-4987234-A AROMATIC ORTHO-DIAMINE AND CARBON DIOXIDE IN WATER; HIGH YIELD HOECHST AKTIENGESELLSCHAFT (DE) 1991-01-22 US disclosed
EP-0355024-A1 Process for the production of cyclic ureas HOECHST AKTIENGESELLSCHAFT (DE) 1990-02-21 EP disclosed
US-4367337-A Process for conversion of benzimidazolones to benzotriazoles THE SHERWIN-WILLIAMS COMPANY (US) 1983-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303516-A1 NOVEL TRIAZINE COMPOUNDS MTOR, MAPKAP1, PIK3R5 CA1 4784/4885CA7 4349/4885CA9 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.